ScienceGlobal issuesCan a new drug benefit Alzheimer’s treatment?04:33This browser does not support the video element.ScienceGlobal issues10/05/2023October 5, 2023In May 2023 a US pharmaceuticals company published the provisional findings from a study on its Alzheimer antibody 'Donanemab'. 47 percent of patients treated with the new compound remained stable.Copy linkAdvertisement
